特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
724042

世界の医薬品・医療機器コンビネーション製品市場:製品、用途、エンドユーザー、地域別 - 市場機会の分析と産業予測 2017年~2025年

Drug-Device Combination Products Market by Product, Application, and End User - Global Opportunity Analysis and Industry Forecast, 2017-2025

出版日: | 発行: Allied Market Research | ページ情報: 英文 244 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.14円
世界の医薬品・医療機器コンビネーション製品市場:製品、用途、エンドユーザー、地域別 - 市場機会の分析と産業予測 2017年~2025年
出版日: 2018年09月01日
発行: Allied Market Research
ページ情報: 英文 244 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の医薬品・医療機器コンビネーション製品市場は、2017年に813億7400万米ドルと評価され、2018年から2025年にかけては6.9%のCAGRで推移し、2025年までに1391億9300万米ドル規模の市場に成長することが予測されています。

当レポートでは、世界の医薬品・医療機器コンビネーション製品市場を調査し、市場の概要、技術・製品・用途・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • レポートの説明
  • ステークホルダーの主な利点
  • 主要な市場セグメント
    • 主要企業
  • 調査方法
    • 2次調査
    • 1次調査
    • アナリストツールとモデル

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な所見
  • 上位企業の市場ポジショニング
  • 政府の規制
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
    • 影響分析
  • 特許分析

第4章 医薬品・医療機器コンビネーション製品市場:製品別

  • 概要
    • 市場規模と予測
  • 薬物溶出ステント
    • 主な市場動向、成長要因、市場機会
    • 市場規模と予測:タイプ別
    • 市場規模と予測:地域別
  • 輸液ポンプ
  • 光線力学療法
  • 抗菌創傷被覆材
  • プレフィルドシリンジ
  • 薬物溶出バルーン
  • ネブライザー
  • 吸入器
  • 経皮送達システム
  • その他

第5章 医薬品・医療機器コンビネーション製品市場:用途別

  • 概要
    • 市場規模と予測
  • 心血管疾患
  • 糖尿病
  • 呼吸器疾患
  • 癌治療
  • 抗菌剤
  • その他

第6章 医薬品・医療機器コンビネーション製品市場:エンドユーザー別

  • 概要
    • 市場規模と予測
  • 病院&診療所
  • 外来外科センター
  • 在宅ケア
  • その他

第7章 医薬品・医療機器コンビネーション製品市場:地域別

  • 概要
    • 市場規模と予測
  • 北米
    • 主な市場動向、成長要因、市場機会
    • 市場規模と予測:国別
    • 市場規模と予測:製品別
    • 市場規模と予測:用途別
    • 市場規模と予測:エンドユーザー別
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第8章 企業プロファイル

  • Abbott Laboratories
  • Bayer AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Johnson & Johnson
  • Medtronic plc
  • GlaxoSmithKline plc
  • Novartis International AG
  • Smith & Nephew plc
図表

List of Tables

  • TABLE 01. MEDICAL DEVICE CLASSIFICATION IN THE U.S.
  • TABLE 02. GLOBAL DRUGS-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
  • TABLE 03. GLOBAL DRUG-ELUTING STENTS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 04. DRUG-ELUTING STENTS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 05. GLOBAL INFUSION PUMPS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 06. INFUSION PUMPS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 07. PHOTODYNAMIC THERAPY SYSTEMS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 08. ANTIMICROBIAL WOUND DRESSINGS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 09. GLOBAL PREFILLED SYRINGES MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 10. PREFILLED SYRINGES MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 11. GLOBAL DRUG-DEVICE COMBINATION INFUSION PUMPS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 12. DRUG-ELUTING BALLOONS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 13. NEBULIZERS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 14. GLOBAL INHALERS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 15. INHALERS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 16. GLOBAL TRANSDERMAL DELIVERY SYSTEMS MARKET, BY TYPE, 2017-2025 ($MILLION)
  • TABLE 17. TRANSDERMAL DELIVERY SYSTEMS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 18. OTHERS DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 19. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 20. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 21. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR DIABETES, BY REGION, 2017-2025 ($MILLION)
  • TABLE 22. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR RESPIRATORY PROBLEMS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 23. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR CANCER TREATMENT, BY REGION, 2017-2025 ($MILLION)
  • TABLE 24. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR ANTIMICROBIAL APPLICATION, BY REGION, 2017-2025 ($MILLION)
  • TABLE 25. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR ANTIMICROBIAL APPLICATION, BY REGION, 2017-2025 ($MILLION)
  • TABLE 26. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY THERAPY, 2017-2025 ($MILLION)
  • TABLE 27. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 28. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR AMBULATORY SURGERY CENTERS (ASCS), BY REGION, 2017-2025 ($MILLION)
  • TABLE 29. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR HOME CARE SETTINGS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 30. DRUG-DEVICE COMBINATION PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2017-2025 ($MILLION)
  • TABLE 31. DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2017-2025 ($MILLION)
  • TABLE 32. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 33. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
  • TABLE 34. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 35. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
  • TABLE 36. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 37. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
  • TABLE 38. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 39. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
  • TABLE 40. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 41. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
  • TABLE 42. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 43. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
  • TABLE 44. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2017-2025 ($MILLION)
  • TABLE 45. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT, 2017-2025 ($MILLION)
  • TABLE 46. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2017-2025 ($MILLION)
  • TABLE 47. LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2017-2025 ($MILLION)
  • TABLE 48. ABBOTT: COMPANY SNAPSHOT
  • TABLE 49. ABBOTT: OPERATING SEGMENTS
  • TABLE 50. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 51. BAYER: COMPANY SNAPSHOT
  • TABLE 52. BAYER: OPERATING PRODUCT SEGMENTS
  • TABLE 53. BAYER: PRODUCT PORTFOLIO
  • TABLE 54. BAXTER: COMPANY SNAPSHOT
  • TABLE 55. BAXTER: OPERATING SEGMENTS
  • TABLE 56. BAXTER: PRODUCT PORTFOLIO
  • TABLE 57. BD: COMPANY SNAPSHOT
  • TABLE 58. BD: FRANCHISES
  • TABLE 59. BD: PRODUCT PORTFOLIO
  • TABLE 60. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 61. BOSTON SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 62. BOSTON SCIENTIFIC: PRODUCT PORTFOLIO
  • TABLE 63. J&J: COMPANY SNAPSHOT
  • TABLE 64. J&J: OPERATING SEGMENTS
  • TABLE 65. J&J: PRODUCT PORTFOLIO
  • TABLE 66. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 67. MEDTRONIC: OPERATING SEGMENTS
  • TABLE 68. MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 69. GSK: COMPANY SNAPSHOT
  • TABLE 70. GSK: OPERATING SEGMENTS
  • TABLE 71. GSK: PRODUCT PORTFOLIO
  • TABLE 72. NOVARTIS: COMPANY SNAPSHOT
  • TABLE 73. NOVARTIS: OPERATING SEGMENTS
  • TABLE 74. NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 75. SMITH & NEPHEW: COMPANY SNAPSHOT
  • TABLE 76. SMITH & NEPHEW: PRODUCT SEGMENTS
  • TABLE 77. SMITH & NEPHEW: PRODUCT PORTFOLIO

List of Figures

  • FIGURE 01. DRUG-DEVICE COMBINATION MARKET SEGMENTATION
  • FIGURE 02. TOP WINNING STRATEGIES (2015-2018)
  • FIGURE 03. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (2015-2018)
  • FIGURE 04. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
  • FIGURE 05. TOP INVESTMENT POCKETS
  • FIGURE 06. TOP PLAYER POSITIONING, 2017
  • FIGURE 07. UNDIAGNOSED PATIENT POPULATION OF DIABETES, 2015 (MILLION)
  • FIGURE 08. IMPACT ANALYSES
  • FIGURE 09. PATENTS REGISTERED/APPROVED IN THE WORLD, BY TYPE OF PRODUCT, 2013-2018
  • FIGURE 10. PATENTS ANALYSIS BY YEAR, 2013 THROUGH 2018
  • FIGURE 11. PATENT ANALYSIS, BY COUNTRY, 2013-2018
  • FIGURE 12. GLOBAL CORONARY DRUG-ELUTING STENTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 13. GLOBAL PERIPHERAL DRUG-ELUTING STENTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 14. GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, 2017-2025 ($MILLION)
  • FIGURE 15. GLOBAL INSULIN INFUSION PUMPS MARKET, 2017-2025 ($MILLION)
  • FIGURE 16. GLOBAL PATIENT-CONTROLLED ANALGESIA PUMPS MARKET, 2017-2025 ($MILLION)
  • FIGURE 17. GLOBAL AMBULATORY INFUSION PUMPS MARKET, 2017-2025 ($MILLION)
  • FIGURE 18. GLOBAL SINGLE-CHAMBER PREFILLED SYRINGES MARKET, 2017-2025 ($MILLION)
  • FIGURE 19. GLOBAL DUAL-CHAMBER PREFILLED SYRINGES MARKET, 2017-2025 ($MILLION)
  • FIGURE 20. GLOBAL CUSTOMIZED PREFILLED SYRINGES MARKET, 2017-2025 ($MILLION)
  • FIGURE 21. GLOBAL CORONARY DRUG-ELUTING BALLOONS MARKET, 2017-2025 ($MILLION)
  • FIGURE 22. GLOBAL PERIPHERAL DRUG-ELUTING BALLOONS MARKET, 2017-2025 ($MILLION)
  • FIGURE 23. GLOBAL DRY POWDER INHALERS MARKET, 2017-2025 ($MILLION)
  • FIGURE 24. GLOBAL METERED DOSE INHALERS MARKET, 2017-2025 ($MILLION)
  • FIGURE 25. GLOBAL SOFT MIST INHALERS MARKET, 2017-2025 ($MILLION)
  • FIGURE 26. GLOBAL ACTIVE TRANSDERMAL SYSTEMS MARKET, 2017-2025 ($MILLION)
  • FIGURE 27. GLOBAL PASSIVE TRANSDERMAL SYSTEMS MARKET, 2017-2025 ($MILLION)
  • FIGURE 28. ESTIMATED NUMBER OF DIAGNOSED AND UNDIAGNOSED DIABETES AMONG ADULTS AGED 18 YEARS, U.S., 2015
  • FIGURE 29. U.S. DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 30. CANADA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 31. MEXICO DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 32. LUNG CANCER INCIDENCE IN THE EUROPEAN REGION, BY GENDER, 2012 (PER 100,000 POPULATION)
  • FIGURE 33. GERMANY DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 34. FRANCE DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 35. UK DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 36. ITALY DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 37. SPAIN DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 38. REST OF EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 39. JAPAN DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 40. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 41. INDIA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 42. AUSTRALIA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 43. SOUTH KOREA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 44. REST OF ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 45. BRAZIL DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 46. SAUDI ARABIA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 47. SOUTH AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 48. REST OF LAMEA DRUG-DEVICE COMBINATION PRODUCTS MARKET, 2017-2025 ($MILLION)
  • FIGURE 49. ABBOTT: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 50. ABBOTT: REVENUE SHARE, BY SEGMENT, 2017 (%)
  • FIGURE 51. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 52. BAYER: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 53. BAYER: REVENUE SHARE, BY SEGMENT, 2017 (%)
  • FIGURE 54. BAYER: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 55. BAXTER: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 56. BAXTER: REVENUE SHARE, BY SEGMENT, 2017 (%)
  • FIGURE 57. BAXTER: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 58. BD: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 59. BD: REVENUE SHARE, BY SEGMENT, 2017 (%)
  • FIGURE 60. BD: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 61. BOSTON SCIENTIFIC: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 62. BOSTON SCIENTIFIC: NET SALES, BY SEGMENT, 2017 (%)
  • FIGURE 63. BOSTON SCIENTIFIC: NET SALES, BY GEOGRAPHY, 2017 (%)
  • FIGURE 64. J&J: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 65. J&J: REVENUE SHARE, BY SEGMENT, 2017 (%)
  • FIGURE 66. J&J: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 67. MEDTRONIC: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 68. MEDTRONIC: NET SALES, BY SEGMENT, 2017 (%)
  • FIGURE 69. MEDTRONIC: NET SALES, BY GEOGRAPHY, 2017 (%)
  • FIGURE 70. GSK: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 71. GSK: REVENUE SHARE, BY SEGMENT, 2017 (%)
  • FIGURE 72. GSK: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 73. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 74. NOVARTIS: REVENUE SHARE, BY PRODUCT, 2017 (%)
  • FIGURE 75. NOVARTIS: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
  • FIGURE 76. SMITH & NEPHEW: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 77. SMITH & NEPHEW: REVENUE SHARE, BY PRODUCT, 2017 (%)
  • FIGURE 78. SMITH & NEPHEW: REVENUE SHARE, BY GEOGRAPHY, 2017 (%)
目次
Product Code: LI_18667

Title:
Drug-Device Combination Products Market by Product (Drug-eluting Stent, Infusion Pump, Photodynamic Therapy, Antimicrobial Wound Dressing, Prefilled Syringe, Drug-eluting Balloon, Nebulizer, Inhaler, Transdermal Delivery System, and Others), Application (Cardiovascular Treatment, Diabetes, Respiratory Problem, Cancer Treatment, Antimicrobial Application, and Others), and End User (Hospital & Clinic, Ambulatory Surgical Center, Home Care Setting, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2025 .

Drug-device combination products comprise of two or more regulated components, which work in coordination. These components involve a medical device, which is used to administer a therapeutic drug in the patient's body. The drug-device combination products can be single products comprising of several components or products packed separately, intended for use with a specialized counterpart. The therapeutic drugs used along with the specific device are either mixed physically or chemically to obtain a resulting mixture for the final use. Currently, the best-known example of drug-device combination product is the drug-eluting stents that are scaffolds coated with a therapeutic drug to prevent growth of tissue scars in an artery.

The global drug-device combination products market was valued at $81,374 million in 2017 and is projected to reach $139,193 million by 2025 at a CAGR of 6.9% from 2018 to 2025. Increase in prevalence of chronic diseases such as diabetes, cardiovascular disorders, respiratory problems, and cancer, drive the growth of the global drug-device combination products market. Further, rise in geriatric population, technological advancements in drug-device combination product, and surge in homebased healthcare market are the other factors that boost the market growth. However, stringent governmental regulations for the approval of combination devices and post-complications and errors lead to numerous product recalls that hinder the growth of the global market. On the contrary, rise in healthcare infrastructure and high market potential in untapped emerging economies are anticipated to serve as lucrative opportunities for market expansion.

The global drug-device combination products market is segmented based on product, application, end user, and region. Based on product, the market is segmented into drug-eluting stent, infusion pump, photodynamic therapy, antimicrobial wound dressing, prefilled syringe, drug-eluting balloon, nebulizer, inhaler, transdermal delivery system, and other products. Drug-eluting stents are further sub-segmented into coronary drug-eluting stent and peripheral drug-eluting stent. The infusion pumps segment is further divided into implantable infusion pumps, insulin infusion pumps, patient-controlled analgesia pumps, and ambulatory infusion pumps. Similarly, prefilled syringes are further categorized into single-chamber prefilled syringes, dual-chamber prefilled syringes, and customized prefilled syringes. The drug-eluting balloons segment is bifurcated into coronary drug-eluting balloons and peripheral drug-eluting balloons. The inhalers segment is further segmented into drug powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). Lastly, transdermal delivery systems segment is divided into passive delivery systems and active delivery systems.

As per application, the market is categorized into cardiovascular diseases, diabetes, respiratory problems, cancer treatment, antimicrobial applications, and other applications. Considering the end-user segment, the market is segregated into hospital & clinic, ambulatory surgery center, home care setting, and other end users. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS:

  • The study provides an in-depth analysis of the global drug-device combination products market with current trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
  • A comprehensive analysis of factors that drive and restrict the market growth is provided.
  • Factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global & regional scale are provided.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

Key Market Segments:

By Product

  • Drug-eluting stent
    • Coronary drug-eluting stent
    • Peripheral drug-eluting stent
  • Infusion pump
    • Implantable infusion pump
    • Insulin infusion pump
    • Patient-controlled analgesia pump
    • Ambulatory infusion pump
  • Photodynamic therapy
  • Antimicrobial wound dressing
  • Prefilled syringe
    • Single-chamber prefilled syringe
    • Dual-chamber prefilled syringe
    • Customized prefilled syringe
    • Drug-eluting balloon
    • Coronary drug-eluting balloon
    • Peripheral drug-eluting balloon
  • Nebulizer
  • Inhaler
    • Drug powder inhaler (DPI)
    • Metered dose inhaler (MDI)
    • Soft mist inhaler (SMI)
  • Transdermal delivery system
    • Passive delivery system
    • Active delivery system
  • Other products

By Application

  • Cardiovascular disease
  • Diabetes
  • Respiratory problem
  • Cancer treatment
  • Antimicrobial application
  • Other applications

By End user

  • Hospital & Clinic
  • Ambulatory Surgery Center (ASCs)
  • Home Care Setting
  • Other end users

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT:

  • Abbott Laboratories
  • Medtronic Plc
  • Smith & Nephew Plc
  • Boston Scientific Corporation
  • GlaxoSmithKline plc
  • Becton, Dickinson and Company
  • Johnson & Johnson
  • Novartis AG
  • Bayer AG
  • Baxter International, Inc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN:

(These players are not profiled in the report. The same will be included on request)

  • B. Braun Melsungen AG
  • Cook Medical
  • ICU Medical, Inc.
  • Moog, Inc.
  • C.R. Bard, Inc.

Table of Contents

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Benefits for Stakeholders
  • 1.3. Key Market Segments
    • 1.3.1. List of key players profiled in the report
  • 1.4. Research Methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. KEY FINDINGS OF THE STUDY
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market Definition and Scope
  • 3.2. Key findings
    • 3.2.1. Top Winning Strategies
    • 3.2.2. Top Investment Pockets
  • 3.3. Top Player Positioning, 2017
  • 3.4. Government Regulations
    • 3.4.1. U.S. FDA
    • 3.4.2. Europe CE Mark
    • 3.4.3. Ministry of Health, Labor, and Welfare (MHLW)
    • 3.4.4. Central Drug Standards Control Organization (CDSCO)
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
      • 3.5.1.1. Rapidly aging population and favorable demographics worldwide
      • 3.5.1.2. Rise in incidence of chronic conditions
      • 3.5.1.3. Technological advancements in drug-device combination products
      • 3.5.1.4. Growth in home-based healthcare market
    • 3.5.2. Restraints
      • 3.5.2.1. Stringent approval process of these products
      • 3.5.2.2. Occurrence of several errors and number of product recalls
    • 3.5.3. Opportunities
      • 3.5.3.1. Opportunities in emerging markets
    • 3.5.4. Impact Analyses
  • 3.6. Patent Analysis (2013-2018)
    • 3.6.1. Patent analysis, by year
    • 3.6.2. Patent analysis, by country

CHAPTER 4: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Drug-Eluting Stents
    • 4.2.1. Key market trends, growth factors, and opportunities
    • 4.2.2. Market size and forecast, by type
      • 4.2.2.1. Coronary Drug-Eluting Stents
      • 4.2.2.1.1. Market size and forecast
      • 4.2.2.2. Peripheral Drug-Eluting Stents
      • 4.2.2.2.1. Market size and forecast
    • 4.2.3. Market size and forecast, by region
  • 4.3. Infusion Pumps
    • 4.3.1. Key market trends, growth factors, and opportunities
    • 4.3.2. Market size and forecast, by type
      • 4.3.2.1. Implantable Infusion Pumps
      • 4.3.2.1.1. Market size and forecast
      • 4.3.2.2. Insulin Infusion Pumps
      • 4.3.2.2.1. Market size and forecast
      • 4.3.2.3. Patient-controlled Analgesia Pumps
      • 4.3.2.3.1. Market size and forecast
      • 4.3.2.4. Ambulatory Infusion Pumps
      • 4.3.2.4.1. Market size and forecast
    • 4.3.3. Market size and forecast, by region
  • 4.4. Photodynamic Therapy
    • 4.4.1. Key market trends, growth factors, and opportunities
    • 4.4.2. Market size and forecast, by region
  • 4.5. Antimicrobial Wound Dressings
    • 4.5.1. Key market trends, growth factors, and opportunities
    • 4.5.2. Market size and forecast, by region
  • 4.6. Prefilled Syringes
    • 4.6.1. Key market trends, growth factors, and opportunities
    • 4.6.2. Market size and forecast, by type
      • 4.6.2.1. Single-Chamber Prefilled Syringes
      • 4.6.2.1.1. Market size and forecast
      • 4.6.2.2. Dual-Chamber Prefilled Syringes
      • 4.6.2.2.1. Market size and forecast
      • 4.6.2.3. Customized Prefilled Syringes
      • 4.6.2.3.1. Market size and forecast
    • 4.6.3. Market size and forecast, by region
  • 4.7. Drug-Eluting Balloons
    • 4.7.1. Key market trends, growth factors, and opportunities
    • 4.7.2. Market size and forecast, by type
      • 4.7.2.1. Coronary Drug-Eluting Balloons
      • 4.7.2.1.1. Market size and forecast
      • 4.7.2.2. Peripheral Drug-Eluting Balloons
      • 4.7.2.2.1. Market size and forecast
    • 4.7.3. Market size and forecast, by region
  • 4.8. Nebulizers
    • 4.8.1. Key market trends, growth factors, and opportunities
    • 4.8.2. Market size and forecast, by region
  • 4.9. Inhalers
    • 4.9.1. Key market trends, growth factors, and opportunities
    • 4.9.2. Market size and forecast, by type
      • 4.9.2.1. Drug powdered inhalers (DPIs)
      • 4.9.2.1.1. Market size and forecast
      • 4.9.2.2. Metered dose inhalers (MDIs)
      • 4.9.2.2.1. Market size and forecast
      • 4.9.2.3. Soft mist inhalers (SMIs)
      • 4.9.2.3.1. Market size and forecast
    • 4.9.3. Market size and forecast, by region
  • 4.10. Transdermal Delivery Systems
    • 4.10.1. Key market trends, growth factors, and opportunities
    • 4.10.2. Market size and forecast, by type
      • 4.10.2.1. Active Transdermal Systems
      • 4.10.2.1.1. Market size and forecast
      • 4.10.2.2. Passive Transdermal Systems
      • 4.10.2.2.1. Market size and forecast
    • 4.10.3. Market size and forecast, by region
  • 4.11. Other products
    • 4.11.1. Key market trends, growth factors, and opportunities
    • 4.11.2. Market size and forecast, by region

CHAPTER 5: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Cardiovascular Disorders
    • 5.2.1. Market size and forecast, by type
  • 5.3. Diabetes
    • 5.3.1. Market size and forecast, by region
  • 5.4. Respiratory Problems
    • 5.4.1. Market size and forecast, by region
  • 5.5. Cancer Treatment
    • 5.5.1. Market size and forecast, by region
  • 5.6. Antimicrobial Application
    • 5.6.1. Market size and forecast, by region
  • 5.7. Other Applications
    • 5.7.1. Market size and forecast, by region

CHAPTER 6: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals & Clinics
    • 6.2.1. Market size and forecast, by region
  • 6.3. Ambulatory Surgery Centers (ASCs)
    • 6.3.1. Market size and forecast, by region
  • 6.4. Home Care Settings
    • 6.4.1. Market size and forecast, by region
  • 6.5. Other End Users
    • 6.5.1. Market size and forecast, by region

CHAPTER 7: DRUG-DEVICE COMBINATION PRODUCTS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors, and opportunities
    • 7.2.2. North America drug-device combination products market, by country
      • 7.2.2.1. U.S.
      • 7.2.2.2. Canada
      • 7.2.2.3. Mexico
    • 7.2.3. North America market size and forecast, by product
    • 7.2.4. North America market size and forecast, by application
    • 7.2.5. North America market size and forecast, by end user
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors, and opportunities
    • 7.3.2. Europe market size and forecast, by country
      • 7.3.2.1. Germany
      • 7.3.2.2. France
      • 7.3.2.3. UK
      • 7.3.2.4. Italy
      • 7.3.2.5. Spain
    • 7.3.3. Rest of Europe
    • 7.3.4. Europe market size and forecast, by product
    • 7.3.5. Europe market size and forecast, by application
    • 7.3.6. Europe market size and forecast, by end user
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors, and opportunities
    • 7.4.2. Asia-Pacific market size and forecast, by country
      • 7.4.2.1. Japan
      • 7.4.2.2. China
      • 7.4.2.3. India
      • 7.4.2.4. Australia
      • 7.4.2.5. South Korea
      • 7.4.2.6. Rest of Asia-Pacific
    • 7.4.3. Asia-Pacific market size and forecast, by product
    • 7.4.4. Asia-Pacific market size and forecast, by application
    • 7.4.5. Asia-Pacific market size and forecast, by end user
  • 7.5. LAMEA
    • 7.5.1. Key market trends, growth factors, and opportunities
    • 7.5.2. LAMEA market size and forecast, by country
      • 7.5.2.1. Brazil
      • 7.5.2.2. Saudi Arabia
      • 7.5.2.3. South Africa
      • 7.5.2.4. Rest of LAMEA
    • 7.5.3. LAMEA market size and forecast, by product
    • 7.5.4. LAMEA market size and forecast, by application
    • 7.5.5. LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating product segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
    • 8.1.6. Key strategic moves and developments
  • 8.2. Bayer AG
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating product segments
    • 8.2.4. Product portfolio
    • 8.2.5. Business performance
  • 8.3. Baxter International Inc.
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Product portfolio
    • 8.3.5. Business performance
    • 8.3.6. Key strategic moves and developments
  • 8.4. Becton, Dickinson and Company
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Product Portfolio
    • 8.4.5. Business performance
    • 8.4.6. Key strategic moves and developments
  • 8.5. Boston Scientific Corporation
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Product Portfolio
    • 8.5.5. Business performance
    • 8.5.6. Key strategic moves and developments
  • 8.6. Johnson & Johnson
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Product Portfolio
    • 8.6.5. Business performance
    • 8.6.6. Key strategic moves and developments
  • 8.7. Medtronic plc
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Product Portfolio
    • 8.7.5. Business performance
    • 8.7.6. Key strategic moves and developments
  • 8.8. GlaxoSmithKline plc
    • 8.8.1. Company Overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Product Portfolio
    • 8.8.5. Business performance
    • 8.8.6. Key strategic moves and developments
  • 8.9. Novartis International AG
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Product portfolio
    • 8.9.5. Business performance
    • 8.9.6. Key strategic moves and developments
  • 8.10. Smith & Nephew plc
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Product portfolio
    • 8.10.5. Business performance
    • 8.10.6. Key strategic moves and developments
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.